Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What Else Can Go Wrong with Permanent Fillers? Side Effects in Sight

Description

In this presentation, Maida Younges, a Brazilian dermatologist, discusses the potential complications associated with permanent fillers, particularly focusing on side effects that can arise from their use. She highlights that complications from permanent fillers, such as nodules, skin hardening, and edema, are more complex to manage compared to temporary fillers, with certain serious adverse reactions like hypercalcemia and renal failure occurring in approximately 20% and 16% of patients, respectively. Younges emphasizes the growing concern around procedures like the Brazilian butt lift, which can involve high volumes of filler, leading to these severe complications. She introduces non-surgical treatment options for managing complications, such as corticosteroids, methotrexate, and Janus kinase (JAK) inhibitors, showcasing case studies where these treatments successfully improved patient conditions. Her own success with JAK inhibitors in treating granulomatous diseases and conditions related to permanent fillers suggests a shift away from surgical interventions toward more effective pharmacological alternatives. Younges concludes by advocating for early intervention and thorough research into immunosuppressive therapies to further improve outcomes for patients experiencing complications from permanent fillers.

View more

Conclusions

  • Less than 8% of certified dermatologists use permanent fillers due to the significant risk of complications.
  • Permanent fillers are associated with serious long-term effects, including nodules, skin hardening, and severe systemic issues like hypercalcemia and renal failure.
  • There is a growing incidence of complications due to increased use of permanent fillers, particularly from procedures like Brazilian butt lifts.
  • Effective treatments for complications from permanent fillers are available, including corticosteroids, methotrexate, and JAK inhibitors, as alternatives to surgery.
  • JAK inhibitors show promise in treating granulomas and other complications associated with permanent fillers, with reported significant improvements in patients.
  • Methotrexate has been shown to produce positive outcomes in patients suffering from complications related to permanent fillers.
  • The emerging use of JAK inhibitors may change the approach to managing complications related to permanent fillers, potentially indicating a shift away from surgical interventions.
  • Barone M, et al. Permanent facial fillers: addressing complications and advancing solutions. Aesthetic Plast Surg. 2024 May 8.
  • lanhez M, et al. Frequency of Complications of Aesthetic Facial Fillers in Brazil. Plast Reconstr Surg. 2022 Mar 1;149(3):599e-601e.
  • lanhez M, Munhoz da Fontoura GH, Miot HÁ et al. Dermatological and nephrological complications after polymethyl methacrylate injections: A series of 239 cases. J Am Acad Dermatol. 2024 Dec 20:S0190-9622(24)03394-2.
  • Conejo-Mir JS, et al. Adverse granulomatous reaction to Artecoll treated by intralesional 5-fluorouracil and triamcinolone injections. Dermatol Surg. 2006;32:1079-1081.
  • Cassuto D et al. Management of complications caused by permanent fillers in the face: a treatment algorithm. PRS 2016;215-27e.
  • Da Silva EAB. Management of permanent complications of facial fillers using microneedling fractionated radiofrequency. Piel 2023;38:307-10.
  • Lemperle G, Gauthier-Hazan N. Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options. Plast Reconstr Surg. 2009;123(6):1864-73.
  • Broly M, et al. Management of granulomatous foreign body reaction to fillers with methotrexate. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):817-820.
  • William Damsky, MD, PhDa, Durga Thakral, PhDa, Meaghan K. McGeary, BAb, Jonathan. NEJM 2019: Case report of a patient with cutaneous sarcoidosis treated with tofacitinib.
  • Miot HA, Criado PR, de Castro CCS, lanhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023 Sep-Oct;98(5):656-677.
  • landau M, et al. Oral Methotrexate Treatment of Delayed-Onset Inflammatory Reactions to Dermal Fillers. Aesthet Surg J Open Forum. 2024 Feb 20;6:ojae011.
  • Kim, 2024; Spinelli, 2021; Alqarni AM, Zeidler MP. How does methotrexate work? Biochem Soc Trans 2020;48:559-67.
  • Lopez MHP et al. Post-hyaluronic acid filler reaction treated with abrocitinib: A case report. J Drugs Dermatol. 2024 Jan 1;23(1):1355-1356.
  • Li Y, et al. Changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis. Mediators Inflamm 2019;2019:5617431.
  • lanhez M, Rodrigues LQ, lanhez LE, Ribeiro RM, Santa Catharina GP, Kroumpouzos G, Miot HA. Hypercalcemia and Renal Complications Following High-Volume Polymethyl Methacrylate (PMMA) Injections: A Case Series. 2025 (Under Review).